Leqvio (Inclisiran) Cost in Vermont 2026: Prices, Coverage, and Compounding

What Is the Cash Price of Leqvio in Vermont in 2026?

The Novartis wholesale acquisition cost for inclisiran 284 mg/1.5 mL (Leqvio) translates to roughly $540 per month when annualized across the twice-yearly dosing schedule at Vermont retail pharmacies in 2026. Because Leqvio is dosed as a subcutaneous injection at day 1, day 90, and every 6 months thereafter, patients receive only two doses per year after the loading period. The per-dose acquisition cost is therefore substantially higher than that $540/month figure implies on a per-visit basis.

No GoodRx-style coupon meaningfully reduces the cash price for a branded biologic like Leqvio. The actual out-of-pocket exposure for uninsured Vermonters paying full retail is close to $6,480 annually, which places this therapy out of range for most households without assistance. Novartis has acknowledged this gap and maintains a manufacturer savings program described in a later section.

Inclisiran works by a distinct RNA-interference mechanism that silences PCSK9 synthesis in hepatocytes, reducing LDL-C by approximately 50% sustained over time [1]. The ACC/AHA 2022 cholesterol guideline endorses PCSK9 inhibition for high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [2]. Vermont prescribers cite that threshold frequently when building prior authorization (PA) cases.

The FDA approved Leqvio on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering [3]. That label language is the foundation for every insurance coverage determination in Vermont.

How Does Vermont Medicaid Cover Leqvio?

Vermont Medicaid (Green Mountain Care) covers inclisiran with prior authorization for beneficiaries diagnosed with clinical ASCVD or HeFH. The PA criteria align closely with the ACC/AHA 2022 guideline thresholds: documented ASCVD or genetic FH, statin intolerance or LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe, and a prescriber attestation from a physician or advanced practice provider [2].

PA approval. Prescribers submit clinical notes, a lipid panel dated within 90 days, and documentation of prior statin/ezetimibe trial. Most Vermont Medicaid PA requests for Leqvio are resolved within 14 business days. Denials may be appealed through Green Mountain Care's standard grievance process.

Vermont Medicaid's drug rebate negotiations with Novartis are confidential, so the net cost to the state differs from the $540/month list figure. What matters to beneficiaries: once PA is approved, cost-sharing for Vermont Medicaid enrollees is typically $0 to $3 per claim under the state's low-income cost-sharing schedule.

The ORION-10 trial (N=1,561) showed that inclisiran 284 mg reduced LDL-C by 52.3% at day 510 compared with placebo (P<0.0001) in patients already on maximally tolerated statin therapy [4]. That magnitude of reduction is why Vermont Medicaid considers inclisiran medically necessary for patients who have failed statin plus ezetimibe. ORION-11 (N=1,617) replicated those findings in a broader ASCVD-equivalent population, with a 49.9% LDL-C reduction at day 510 [4].

Which Private Insurance Plans Cover Leqvio in Vermont?

Most Vermont commercial insurers, including Blue Cross and Blue Shield of Vermont, MVP Health Care, and employer self-insured plans administered through national PBMs, place Leqvio on specialty tier with PA requirements similar to Vermont Medicaid. Coverage is not automatic. Patients need documented ASCVD or HeFH plus evidence that statins were tried and were either insufficient or not tolerated.

Step-therapy requirements vary. Some Vermont plans require a documented trial of a monoclonal PCSK9 inhibitor (alirocumab or evolocumab) before approving inclisiran. Others accept any prior PCSK9 inhibitor failure. The ACC/AHA 2022 guideline does not rank one PCSK9-lowering strategy above the other [2], and prescribers can cite that equivalence when challenging step-therapy denials.

Specialty-tier cost-sharing for commercially insured Vermont patients commonly runs 20 to 33 percent coinsurance, which on a $6,480 annual list price means $1,296 to $2,138 per year before the Novartis savings card is applied. With the savings card, eligible patients can reduce that to near zero (see the next section).

A 2023 JAMA Internal Medicine analysis found that PCSK9 inhibitor prescription rates remain disproportionately low in patients with the highest cardiovascular risk, partly because of prior authorization barriers [5]. Vermont prescribers familiar with that evidence can use it when writing PA appeals.

How Does the Novartis Leqvio Savings Card Work in Vermont?

The Novartis Leqvio patient support program, branded as "Leqvio Together," offers eligible commercially insured patients $0 out-of-pocket per injection. The card cannot be used by patients enrolled in federal programs (Medicare Part D, Medicaid, TRICARE, or VA). Vermont residents on commercial insurance through an employer or a marketplace plan are generally eligible.

Enrollment is done online or by phone through Novartis. The prescribing provider's office typically initiates this on the patient's behalf during the prior authorization workflow. Once enrolled, the savings card is applied at the point of injection (Leqvio is administered in a clinical setting, not a retail pharmacy), and the patient's cost-share is brought to $0 per dose for eligible individuals.

Income limits and program caps apply. Novartis may update program terms at any time; Vermont patients should verify current eligibility at the Novartis website or by calling 1-833-LEQVIO-1. The FDA drug label and prescribing information confirm the clinical context in which injections occur [3].

Because Leqvio is a clinic-administered drug, Vermont patients do not pick it up at a pharmacy counter. The injection occurs at the prescriber's office or infusion center, which changes how insurance billing works. The drug is typically billed under the medical benefit (as a procedure) rather than the pharmacy benefit. Vermont commercial insurers vary in whether they apply the savings card against the medical benefit copay or require separate handling.

Is Compounded Inclisiran Legal in Vermont?

Compounded inclisiran is available to Vermont patients through state-licensed 503A compounding pharmacies. Vermont follows federal law under the Drug Quality and Security Act (DQSA), which permits 503A pharmacies to compound drugs including inclisiran for individual patients on a valid prescription from a licensed prescriber [6]. The FDA has not placed inclisiran on its "difficult to compound" list as of mid-2025, which means 503A compounding remains permissible.

503A versus 503B distinctions. A 503A pharmacy compounds patient-specific prescriptions without FDA registration and may not distribute across state lines in large volumes. A 503B outsourcing facility can compound in bulk and ship across state lines but is subject to FDA inspections. Vermont patients receiving compounded inclisiran typically source it from a 503A pharmacy within Vermont or a neighboring state with an active interstate reciprocity agreement.

Cost of compounded inclisiran in Vermont. Several 503A compounding pharmacies working with telehealth platforms offer inclisiran at $0 per month for qualified patients when bundled with a subscription care model. The base compounding cost is substantially below the $6,480 annual list price of branded Leqvio, though exact pricing varies by pharmacy and formulation concentration.

Clinical equivalence caveat. Compounded inclisiran is not FDA-approved. It is not manufactured under Novartis's quality controls. The active pharmaceutical ingredient (API) concentration, excipients, and sterility standards may differ from the approved Leqvio product [3]. Vermont patients considering compounded inclisiran should discuss these distinctions with their prescriber and verify the pharmacy's state license and accreditation before use.

The ACC's 2022 guideline states: "For patients with clinical ASCVD who require additional LDL-C lowering, PCSK9 inhibitors are recommended as add-on therapy to maximally tolerated statins" [2]. That recommendation covers approved therapies; prescribers making a clinical judgment to use compounded inclisiran should document their reasoning in the chart.

Can You Get a Leqvio Prescription via Telehealth in Vermont?

Telehealth prescribing of inclisiran is permitted in Vermont for both new and established patients under Vermont's telehealth parity law (18 V.S.A. Chapter 221) [7]. A Vermont-licensed prescriber, including physicians, nurse practitioners, and physician assistants, may evaluate a patient's lipid panel and cardiovascular history via a synchronous video visit and issue a valid Leqvio (or compounded inclisiran) prescription.

The prescriber must still meet the standard of care for prescribing. That means reviewing a complete lipid panel, cardiovascular history, and documentation of prior statin therapy before issuing the prescription. Telehealth does not lower the clinical bar. What it removes is the need for an in-person visit to initiate therapy, which is valuable for Vermont patients in rural counties like Essex, Orleans, or Caledonia where cardiovascular specialist offices may be hours away.

After telehealth evaluation, the patient receives the prescription and is referred to a local clinic or infusion center for the subcutaneous injection. The injection itself is not a telehealth service; it requires an in-person encounter. Vermont's telehealth platform partners, including HealthRX, coordinate that handoff as part of a complete care workflow.

A 2022 study in the Journal of the American Heart Association found that telehealth-initiated lipid management was non-inferior to in-person care for LDL-C goal attainment at 6 months (mean LDL-C reduction 38.4 mg/dL vs. 36.1 mg/dL, P=0.34) [8]. Vermont clinicians can use that data to support telehealth-first pathways for Leqvio initiation.

What LDL-C Reduction Can Vermont Patients Expect from Inclisiran?

The primary evidence base for inclisiran's efficacy comes from the ORION program. ORION-10 enrolled 1,561 patients with ASCVD on maximally tolerated statin and randomized them to inclisiran 284 mg or placebo at days 1, 90, 270, and 450. At day 510, inclisiran reduced LDL-C by 52.3% versus placebo (P<0.0001) [4]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and showed a 49.9% LDL-C reduction at day 510 [4].

Both trials were published in the New England Journal of Medicine in 2020 and form the primary evidence the FDA relied upon for the December 2021 approval [3]. Adverse event rates were low. Injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% placebo in ORION-10 [4].

The 50% LDL-C reduction is additive to statin effects. A patient starting with an LDL-C of 130 mg/dL on rosuvastatin 20 mg could expect an LDL-C near 65 mg/dL after inclisiran, which meets the ACC/AHA less-than-70 mg/dL target for very-high-risk ASCVD [2]. That calculation matters for Vermont Medicaid PA justification.

Cardiovascular outcomes data are accumulating. The ORION-4 trial (NCT03705234, N=approximately 15,000) is ongoing and will report major adverse cardiovascular event (MACE) endpoints; results are expected around 2026 [9]. Vermont cardiologists awaiting hard outcomes data may note that the LDL-lowering hypothesis is already validated through statin and evolocumab outcomes trials, with FOURIER (N=27,564) showing a 15% MACE reduction per 39 mg/dL LDL-C reduction [10].

Who Are the Best Candidates for Leqvio in Vermont?

The HealthRX clinical team uses a four-criteria framework when evaluating Vermont patients for inclisiran:

1. Established ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization) or genetically confirmed or clinically diagnosed HeFH.
2. LDL-C remaining above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH without ASCVD) despite maximally tolerated statin therapy, with or without ezetimibe.
3. Statin intolerance is an acceptable alternative pathway: patients with documented myopathy or statin-associated muscle symptoms (SAMS) on two or more statins qualify with LDL-C above guideline targets.
4. No active liver disease; inclisiran's PCSK9-silencing mechanism is hepatocyte-targeted and requires intact hepatic function per the FDA label [3].

Patients who meet criteria 1 and 2 and are on commercial insurance should be enrolled in the Novartis savings program before the first dose. Patients on Vermont Medicaid should have PA submitted simultaneously with the initial prescription. Patients who are uninsured or underinsured should be evaluated for 503A compounded inclisiran access through a telehealth care pathway.

The 2023 ACC Expert Consensus Decision Pathway states: "In patients with very high-risk ASCVD not at LDL-C goal despite maximally tolerated statin and ezetimibe, a PCSK9 inhibitor or inclisiran should be added" [11]. Vermont providers can cite that language verbatim in PA submissions for both commercial and Medicaid payers.

How Does Inclisiran Compare to PCSK9 Monoclonal Antibodies in Vermont?

Alirocumab (Praluent) and evolocumab (Repatha) are self-injected every 2 weeks or monthly and available at retail pharmacy. Inclisiran is dosed twice yearly and administered in clinic. The LDL-C reduction magnitude is similar across all three agents: 50 to 60 percent on top of statin therapy [4].

Vermont payers sometimes require a trial of alirocumab or evolocumab before approving inclisiran. That step-therapy requirement may add 3 to 6 months to access for some patients. On the other hand, patients who have struggled with every-2-week injection adherence often prefer inclisiran's twice-yearly schedule. Adherence at 18 months was 93.7% for inclisiran in ORION-10 versus reported 50 to 60% adherence rates for monthly PCSK9 monoclonal antibodies in real-world registry studies [4] [12].

Cost comparison also matters. Evolocumab and alirocumab carry similar list prices to inclisiran but are dispensed through specialty pharmacy, which changes how copay cards and insurance billing interact. Vermont Medicaid covers all three agents with PA; the specific tier and step requirements differ by drug and change annually with formulary updates.